Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival

@inproceedings{Iqbal2017PrimaryCC,
  title={Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival},
  author={Muhammad Shahid Iqbal and Cheng Shu Chaw and Josef Kovarik and Shahzeena Aslam and Aaron Jackson and John A. Kelly and Werner Dobrowsky and Charles J. Kelly},
  booktitle={International archives of otorhinolaryngology},
  year={2017}
}
Introduction Concurrent chemoradiation is the standard of care in inoperable locally advanced squamous cell head and neck cancers. The most widely accepted schedule of concomitant cisplatin is 100mg/m2 given on a 3 weekly basis but the optimal regime is unknown. Objective The objective of this study is to assess the tolerability, compliance, and clinical outcomes of weekly cisplatin (40mg/m2). Methods During the period of January 2007-December 2009, we analyzed retrospectively 122 patients with… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Meta - analysis of chemotherapy in head and neck cancer ( MACHNC ) : an update on 93 randomised trials and 17 , 346 patients

JP Pignon, A leMaître, E Maillard, J Bourhis
Radiother Oncol • 2009

Similar Papers

Loading similar papers…